# info@crystallizationsummit.com

Category : 2024 Speakers

Process Development and Robust Control of Physical Attributes of an Amorphous Drug Substance

By Dr. Dimitrios Zarkadas, Ph.D. Director, Merck & Co Control of physical attributes of amorphous Active Pharmaceutical Ingredients (APIs) can be challenging due to processability issues, their wide variation...

Dr. Dimitrios Zarkadas, Merck & Co, USA

Dr. Dimitrios Zarkadas has 20 years of experience in API development, commercialization and lifecycle management. He is currently leading API lifecycle management and development activities for the Merck Animal...

Learnings from Solid Form Development of Complex HCV Drugs

By Dr. Shuang Chen, Ph.D. Senior Principal Scientist, AbbVie In recent years, more and more structurally diverse and complex molecules have been developed to tackle difficult but attractive drug...

Dr. Shuang Chen, AbbVie

Shuang Chen is currently a Senior Principal Scientist in Small Molecule CMC Development organization at AbbVie. He has over 18 years of pharmaceutical development experience with specialties in molecular...

Dr. Noalle Fellah, Pfizer

Dr. Noalle Fellah is a Senior Scientist in the Crystallization Technology Lab (CTL) within Chemical Research and Development (CRD) at Pfizer, Inc. Noalle earned her PhD in Chemistry from...

Developing and optimizing a quench-crystallization operation in drug substance manufacturing

By Mr. James D. Fostinis, Ph.D. Drug Substance Technologies Engineer, Amgen Quench crystallization approaches provide unique opportunities to design and control crystallization of pharmaceutically-relevant compounds, which can help streamline...

Mr. James D. Fostinis, Amgen

Jim Fostinis is an Engineer within the Drug Substance Technologies – Synthetics team in Process Development at Amgen. During his time at Amgen, Jim has focused on small molecule...

Peptide crystallisation

By Prof. Jerry Heng, Ph.D. Professor, Department of Chemical Engineering at Imperial College The purification of high molecular weight new modalities such as peptides, for their use in biopharmaceutical...

Prof. Jerry Heng, Imperial College, UK

Jerry Heng (JH) is currently a Professor in Particle Technology and Director of UG Studies at the Department of Chemical Engineering at Imperial College London. JH obtained his PhD in Chemical Engineering from...

Addressing poor solubility and oiling-out tendencies of drug substances

By Dr. Lotfi Derdour, Ph.D. Associate director, GlaxoSmithKline In recent years, there has been a increase in challenges related to low solubility1 and propensity for oiling-out2 in active pharmaceutical...

RSS
Follow by Email
LinkedIn
Share